|0.6962 0.015 (2.22%)||12-05 15:57|
|Targets||6-month :||0.81||1-year :||0.95|
|Resists||First :||0.69||Second :||0.81|
|Supports||First :||0.63||Second :||0.58|
|MAs||MA(5) :||0.68||MA(20) :||0.66|
|MA(100) :||0.78||MA(250) :||0.88|
|MACD||MACD :||0||Signal :||-0.1|
|%K %D||K(14,3) :||82.3||D(3) :||85.4|
|52-week||High :||1.49||Low :||0.55|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ONTX ] has closed below upper band by 40.6%. Bollinger Bands are 36% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||0.7 - 0.7||0.7 - 0.71|
|Low:||0.65 - 0.66||0.66 - 0.66|
|Close:||0.67 - 0.67||0.67 - 0.68|
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||21 (M)|
|Held by Insiders||2.085e+007 (%)|
|Held by Institutions||0.5 (%)|
|Shares Short||65 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-8 %|
|Return on Assets (ttm)||928 %|
|Return on Equity (ttm)||-38.1 %|
|Qtrly Rev. Growth||226000 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||-49.3|
|Qtrly Earnings Growth||-1 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-17 (M)|
|Price to Book value||0|
|Price to Sales||-0.02|
|Price to Cash Flow||1.66|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|